CTOs on the Move

Vyripharm Enterprises

www.vyripharmbio.com

 
Vyripharm® is a disruptive biopharmaceutical innovator in personalized medicine. We are challenging the status quo by shifting medical paradigms through the integration of traditional and alternative medicines. Our purpose is to push the boundaries to drive innovation by turning groundbreaking science into cutting edge diagnostics and therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Stembanc

Stembanc is a Chardon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nano Mark

Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hapbee

Hapbee is the only wearable wellness technology that delivers the molecular signature of compounds (like melatonin, caffeine, CBD and many others) through magnetic waves - so you can experience the benefits digitally without any of the side effects. It puts you in control of your wellness.

Clinical Data

Clinical Data, Inc. is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.